September 18, 2014 | The Israeli Parkinson’s drug developer NeuroDerm has filed a prospectus to raise up to $65 million in a NASDAQ IPO, at a company value of $200 million, after money. The company, which develops treatments for Parkinson’s disease currently undergoing clinical trials, filed the IPO prospectus confidentially this past April. NeuroDerm’s main shareholders are Capital Point, Chairman and Omrix Biotechnology founder Robert Taub and board members Uwe Wascher and Shmuel Cabilly. Jefferies and Cowen & Company are the joint bookrunners for the deal, with the company trading under the ticker symbol NDRM. NeuroDerm was founded in 2003 and has developed two treatments for Parkinson’s disease currently undergoing clinical trials, including a wearable ‘belt’ treatment for the continued administration of the treatment drug Levodopa.